Abstract
Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have